No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

Meridian Medical Technologies, a Kindeva Drug Delivery Company, Investing $100+ Million in Bridgeton, Missouri, Expansion

Editor: What To Know

  • “Building a broader platform with the latest technologies and equipment available, coupled with enhanced capabilities in the production of pre-filled syringes and cartridges, will enable Meridian to offer a broader array of CDMO services and increased capacity to our customers.
  • Meridian Medical Technologies, a Kindeva Drug Delivery Company, a leading global contract development and manufacturing organization (CDMO) focused on drug-device combination products, announced today, during National Community Development Week, it will expand manufacturing capabilities in Bridgeton, Missouri — investing more than $100 million over the next four years in a newly purchased facility.
  • It is exciting to see a company like Meridian recognize the potential in our region, and we look forward to the positive impact they will have on our community.

Meridian Medical Technologies, a Kindeva Drug Delivery Company, a leading global contract development and manufacturing organization (CDMO) focused on drug-device combination products, announced today, during National Community Development Week, it will expand manufacturing capabilities in Bridgeton, Missouri — investing more than $100 million over the next four years in a newly purchased facility. Meridian, which recently combined with Kindeva, will be converting this new 155,000-square-foot facility to support increased production of drug-device combination products, sterile fill-finish capabilities, and create job opportunities in the St. Louis area.

“We’re proud to have a leading, high-tech manufacturer like Meridian Medical Technologies expanding in St. Louis,” said Gov. Mike Parson. “It’s always exciting to see a local employer thriving, creating jobs, and developing innovative products right here in our state. We wish Meridian the best and look forward to its future growth as it continues to succeed in the region.”

Meridian founded the autoinjector technology and has been a leading manufacturer of emergency autoinjectors for more than 60 years. Now with Kindeva, the combined company has a broader range of drug delivery capabilities that this Bridgeton facility investment will help support worldwide.

“Meridian brings a strong history of specific expertise to support critical manufacturing capabilities for complex products — addressing a manufacturing shortage we have seen increase over the last several years,” said Milton Boyer, Meridian CEO. “Building a broader platform with the latest technologies and equipment available, coupled with enhanced capabilities in the production of pre-filled syringes and cartridges, will enable Meridian to offer a broader array of CDMO services and increased capacity to our customers.”

Since January 2022, Meridian has added approximately 300 employees for a total of approximately 900 in the St. Louis area. The company’s new facility, which will be completed in 2024, will support continued growth by dramatically increasing its abilities to develop and manufacture products that will bring new medicines to new markets and customers worldwide.

For this expansion, Meridian will benefit from the Missouri Works program, a tool that helps companies expand and retain workers by providing access to capital through withholdings or tax credits for job creation.

“It’s exciting to see Meridian Medical Technologies create more opportunities for Missourians in St. Louis,” said Maggie Kost, Acting Director of the Department of Economic Development. “As Meridian expands while developing lifesaving products, we’re grateful to support its growth. This company is another example of a quality local employer making a positive difference for our state and beyond.”

What Others Are Saying

“The city of Bridgeton welcomes Meridian Medical Technologies to the city,” said Mayor Terry Briggs. “Not only will Meridian bring well-paying jobs to our city, but the medical products it develops here will help countless people throughout the world. We look forward to working with them.”

“The expansion of Meridian Medical Technologies is a significant step forward for St. Louis,” said County Councilwoman Kelli Dunaway. “Their investment in our community not only brings economic benefits, but also underscores St. Louis’ position as a hub for innovation and advancement in the healthcare industry. It is exciting to see a company like Meridian recognize the potential in our region, and we look forward to the positive impact they will have on our community.”

“The expansion of Meridian Medical Technologies will provide more jobs and increase production in St. Louis County,” said County Executive Dr. Sam Page. “With the help of the St. Louis Economic Development Partnership, we have worked to create a path for growth to a business that employs approximately 900 people in St. Louis County.”

“Meridian’s expansion brings not only new investment and new jobs to the St. Louis metro, but highlights the continued growth of our bioscience and advanced manufacturing sectors,” said Jason Hall, CEO of Greater St. Louis, Inc. “We are excited by Meridian’s expansion and their commitment to St. Louis and appreciate the hard work and collaboration of the economic development partners at the state and regional level who helped make this project happen.”

“The St. Louis region has so much to offer in the biosciences and medical industry. We are excited Meridian Medical Technologies will be expanding its operations here and bringing more jobs to Missouri,” said Tara Oglesby, Vice President of Community, Economic Development and Energy Solutions at Ameren Missouri. “Ameren Missouri’s Smart Energy Plan continues to be instrumental in making the region more attractive for businesses to grow here while also providing reliable energy to power the quality of life for the customers and communities we serve.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy